Guardian Pharmacy Services, Inc. (NYSE:GRDN) Receives Consensus Rating of “Moderate Buy” from Analysts

Guardian Pharmacy Services, Inc. (NYSE:GRDN) has received a consensus recommendation of “Moderate Buy” from the five research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $32.00.

GRDN has been the topic of a number of research reports. Truist Financial upped their price target on shares of Guardian Pharmacy Services from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, November 14th. Weiss Ratings restated a “hold (c+)” rating on shares of Guardian Pharmacy Services in a report on Monday, December 29th. Stephens increased their target price on Guardian Pharmacy Services from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 14th. Finally, Wall Street Zen raised Guardian Pharmacy Services from a “buy” rating to a “strong-buy” rating in a report on Monday, November 17th.

Institutional Investors Weigh In On Guardian Pharmacy Services

A number of institutional investors have recently modified their holdings of GRDN. Boston Partners raised its stake in Guardian Pharmacy Services by 418.7% in the 3rd quarter. Boston Partners now owns 1,046,877 shares of the company’s stock worth $26,922,000 after purchasing an additional 845,048 shares in the last quarter. TimesSquare Capital Management LLC bought a new position in shares of Guardian Pharmacy Services during the second quarter worth approximately $17,351,000. Millennium Management LLC raised its position in shares of Guardian Pharmacy Services by 725.2% in the third quarter. Millennium Management LLC now owns 342,038 shares of the company’s stock valued at $8,972,000 after buying an additional 300,587 shares in the last quarter. Aristotle Capital Boston LLC boosted its stake in shares of Guardian Pharmacy Services by 58.5% in the third quarter. Aristotle Capital Boston LLC now owns 649,463 shares of the company’s stock valued at $17,035,000 after buying an additional 239,790 shares during the period. Finally, Franklin Resources Inc. boosted its stake in shares of Guardian Pharmacy Services by 32.2% in the second quarter. Franklin Resources Inc. now owns 976,207 shares of the company’s stock valued at $20,803,000 after buying an additional 237,630 shares during the period.

Guardian Pharmacy Services Trading Up 2.9%

GRDN opened at $33.84 on Friday. The stock’s fifty day simple moving average is $30.38 and its 200 day simple moving average is $27.51. Guardian Pharmacy Services has a 1-year low of $17.78 and a 1-year high of $37.43. The stock has a market cap of $2.14 billion, a PE ratio of 53.71 and a beta of 0.96.

Guardian Pharmacy Services (NYSE:GRDN) last released its quarterly earnings data on Monday, November 10th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.24 by $0.01. The firm had revenue of $377.43 million for the quarter, compared to the consensus estimate of $381.16 million. Guardian Pharmacy Services had a net margin of 2.90% and a return on equity of 30.29%. Equities analysts forecast that Guardian Pharmacy Services will post 0.87 earnings per share for the current year.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.